News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact

Newspapers

> GlaxoSmithKline CEO Emma Walmsley outlined her fix for the company's long-standing pipeline woes. The plan is to give the commercial team a bigger say in pipeline decisions. Article 

> Leo Pharma formed a research collaboration with HitGen. The agreement will see HitGen turn its technology on targets of interest to Leo. Statement 

> Alligator Bioscience expanded its immuno-oncology collaboration with Stanford University. Release 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.